NORWEGIAN PHARMA AS

Operating

Omega-3 products of highest quality | Norwegian Pharma,Omega-3 products of highest quality | Norwegian Pharma

Norwegian Omega-3 has been created around a simple objective: To make the purest multipurpose omega-3 possible.,Norwegian Omega-3 has been created around a simple objective: To make the purest multipurpose omega-3 possible. We wanted to make it easy for those who simply want the best.

Drive handel med naturprodukter, herunder eksport av samme, samt hva hermed står i naturlig forbindelse. Selskapet kan også opptre som interessent i andre foretagender, ved aksjetegning eller på annen måte.

Handel med naturprodukter.

Organization

CEO: AL
Arve Leroux Høgemark1972
Chairman of the board: FH
Fredrik Haven1987
Years since formation: 17 years; since Mar 10, 2009
Type: Limited company
VAT registered: Yes
Number of employees: 0

Ownership

Number of shares and share classes: 100; 1 share class
Total number of shareholders: 5; 3 companies, 2 persons

Financials

Total operating income 2025: 8,547,892; NOK
Annual total result 2025: 1,057,284; NOK
Total equity 2025: 2,866,728; NOK

Last update: May 4, 2026

Management

Management / administration

Name	Role	Shares
AL Arve Leroux Høgemark 1972	Managing Director/CEO	-

Board

Name	Role	Shares
FH Fredrik Haven 1987	Chairman	20 % directly
OF Ole Fredrik Haven 1953	Board Member	20 % indirectly
PM Pål Michael Smith 1971	Board Member	20 % indirectly
SN Stig Nordsveen 1970	Board Member	14 % indirectly
AL Arve Leroux Høgemark 1972	Board Member	-

Others

Name	Role	Shares
S SOLHØI REVISJON AS	Auditor	-
A ALL-REGNSKAPSERVICE AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
FH Fredrik Haven 1987	Chairman	20 % directly
AH Arve Høgemark 1972	-	20 % directly
OF Ole Fredrik Haven 1953	Board Member	20 % indirectly
PM Pål Michael Smith 1971	Board Member	20 % indirectly
SN Stig Nordsveen 1970	Board Member	14 % indirectly
ON Oscar Nordsveen 2005	-	3 % indirectly

Last update: May 28, 2026

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
F FATTER & GUTTA AS	Ordinary shares	20	20 %
A ALVIRO AS	Ordinary shares	20	20 %
H HAVEN FINANS AS	Ordinary shares	20	20 %
AH Arve Høgemark 1972	Ordinary shares	20	20 %
FH Fredrik Haven 1987	Ordinary shares	20	20 %

Last update: Jun 2, 2025

Financials

in NOK

Summary

Year	2025	2024	2023	2022
Total operating income	8,547,892	10,960,739	10,039,483	10,862,203
Annual Total Result	1,057,284	1,252,154	1,237,250	1,573,694
Total assets	3,953,378	4,384,947	6,011,779	6,879,881
Total liabilities	1,086,650	1,075,503	1,704,489	1,809,841
Total equity	2,866,728	3,309,444	4,307,291	5,070,040

P&L

Year	2025	2024	2023	2022
Total operating income	8,547,892	10,960,739	10,039,483	10,862,203
Total operating costs	7,204,317	9,432,189	8,517,463	8,840,622
Operating result	1,343,576	1,528,550	1,522,019	2,021,581
Financial income/costs	21,126	81,777	67,799	-6
Profit before tax	1,364,702	1,610,327	1,589,818	2,021,574
Total tax & extraordinary income/cost	307,418	358,173	352,568	447,880
Annual Total Result	1,057,284	1,252,154	1,237,250	1,573,694

Balance overview

Year	2025	2024	2023	2022
Total fixed assets	0	0	0	0
Total current assets	3,953,378	4,384,947	6,011,779	6,879,881
Total assets	3,953,378	4,384,947	6,011,779	6,879,881
Short term debt	1,075,442	1,062,463	1,704,489	1,809,841
Long term debt	11,208	13,040	0	0
Total liabilities	1,086,650	1,075,503	1,704,489	1,809,841
Contributed capital	100,000	100,000	100,000	100,000
Retained earnings	2,766,728	3,209,444	4,207,291	4,970,040
Total equity	2,866,728	3,309,444	4,307,291	5,070,040
Total equity and liabilities	3,953,378	4,384,947	6,011,779	6,879,881

Classification

21st company classification

BETA

Small company

Type of organization

Limited company

Classification of institutional sector

INNL

Domestic sectors

A_IKKE-FIN

Non-financial corporations

2100

Private non-financial incorporated enterprises

NORWEGIAN PHARMA AS893 844 422